54815-23-5

Basic information

• Product Name: 4-Amino-α,α-dimethylbenzeneacetic acid methyl ester
• Synonyms: 4-Amino-α,α-dimethylbenzeneacetic acid methyl ester;Methyl 2-(4-aminophenyl)-2-methylpropanoate
• CAS NO: 54815-23-5
• Molecular Formula: C₁₁H₁₅NO₂
• Molecular Weight: 193.2423
• Mol File: 54815-23-5.mol
• Article Data: 18

Chemical Properties

• Melting Point: 80-84 °C
• Boiling Point: 297.5±23.0 °C(Predicted)
• Appearance: /
• Density: 1.083±0.06 g/cm3(Predicted)
• PKA: 4.04±0.10(Predicted)
• CAS DataBase Reference: 4-Amino-α,α-dimethylbenzeneacetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-α,α-dimethylbenzeneacetic acid methyl ester(54815-23-5)
• EPA Substance Registry System: 4-Amino-α,α-dimethylbenzeneacetic acid methyl ester(54815-23-5)

Safety Data

• Hazardous Substances Data: 54815-23-5(Hazardous Substances Data)

Usage

Description

4-Amino-α,α-dimethylbenzeneacetic acid methyl ester, also known as Methyl 2-(4-aminophenyl)-2-methylpropanoate, is an organic compound with a unique chemical structure that features an amino group, a methyl ester group, and a dimethylbenzeneacetic acid moiety. This versatile molecule has potential applications in various fields due to its reactivity and functional groups.

Uses

Used in Pharmaceutical Industry:
4-Amino-α,α-dimethylbenzeneacetic acid methyl ester is used as a reactant/reagent for the preparation of amide compounds that possess RORyt inhibitory effects. These amide compounds are of interest in the development of new drugs targeting the RORyt receptor, which plays a role in various biological processes and diseases.
In the synthesis of such amide compounds, 4-Amino-α,α-dimethylbenzeneacetic acid methyl ester serves as a key building block, providing the necessary functional groups for the formation of the desired amide linkage. This makes it a valuable component in the design and synthesis of potential therapeutic agents targeting the RORyt receptor, with potential applications in treating various diseases and conditions where RORyt plays a significant role.

Upstream product

• 59115-08-1 methyl 2-methyl-2-(4-nitrophenyl)propanoate 
• 31469-15-5 1-methoxy-2-methyl-1-trimethylsiloxy-1-propene 
• 106-47-8 4-chloro-aniline 
• 915084-42-3 2-(4-(benzyloxycarbonylamino)phenyl)-2-methylpropanoic acid methyl ester 
• 42206-47-3 2-methyl-2-(4-nitro-phenyl)-propionic acid 

Downstream Products

• 756813-88-4 metyl 2-(4-amino-3-iodophenyl)-2-methylpropanoate 
• 1236409-53-2 ethyl N-[4-(2-methoxy-1,1-dimethyl-2-oxoethyl)phenyl]-beta-alaninate 
• 1229705-37-6 2-(4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-phenyl)-2-methyl-propionic acid methyl ester 
• 1375702-51-4 methyl 2-[4-(4-benzylpiperazin-1-yl)phenyl]-2-methylpropanoate 
• 1095540-43-4 methyl 2-methyl-2-[4-(piperazin-1-yl)phenyl]propanoate 
• 1375702-24-1 methyl 2-(4-{4-[5-(5-chloro-1H-benzimidazol-2-yl)pyridin-2-yl]piperazin-1-yl}phenyl)-2-methylpropanoate 
• 1375701-89-5 2-(4-{4-[5-(5-chloro-1H-benzimidazol-2-yl)pyridin-2-yl]piperazin-1-yl}phenyl)-2-methylpropanoic acid 
• 476429-12-6 2-(N,N-dimethyl-4-aminophenyl)-2-methylpropionic acid methyl ester 

Relevant articles and documents

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

Novel propanamides as fatty acid amide hydrolase inhibitors

Fatty acid amide hydrolase (FAAH) has a key role in the control of the cannabinoid signaling, through the hydrolysis of the endocannabinoids anandamide and in some tissues 2-arachidonoylglycerol. FAAH inhibition represents a promising strategy to activate the cannabinoid system, since it does not result in the psychotropic and peripheral side effects characterizing the agonists of the cannabinoid receptors. Here we present the discovery of a novel class of profen derivatives, the N-(heteroaryl)-2-(4-((2-(trifluoromethyl)pyridin-4-yl)amino)phenyl)propanamides, as FAAH inhibitors. Enzymatic assays showed potencies toward FAAH ranging from nanomolar to micromolar range, and the most compounds lack activity toward the two isoforms of cyclooxygenase. Extensive structure-activity studies and the definition of the binding mode for the lead compound of the series are also presented. Kinetic assays in rat and mouse FAAH on selected compounds of the series demonstrated that slight modifications of the chemical structure could influence the binding mode and give rise to competitive (TPA1) or non-competitive (TPA14) inhibition modes.

4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES

The invention provides compounds of the general Formula (I) where R1, R2, and A are defined herein, as well as the preparation, compositions and uses thereof.